Update on Therapeutic potential of emerging nanoformulations of phytocompounds in Alzheimer's and Parkinson's disease

Abstract

The prevalence of neurodegenerative disorders (NDs) has increased recently, with Parkinson's disease (PD) and Alzheimer's disease (AD) being the two utmost prevalent ones. As a result of the various defensive barriers that enclose the central nervous system (CNS), drug administration to the brain continues to be the most difficult aspect of treating all neurodegenerative illnesses. One of the novel methods for treating a wide range of disorders, including different types of cancer, neuronal issues, and infectious diseases, is nanotechnology. Currently, nanotechnology-based medicine has emerged as an effective treatment method for NDs. Therapeutics for AD and PD, which can target and administer medications across the blood-brain barrier (BBB), have created an interesting novel field for nanoformulation-based therapies. The exciting interface existing between medicinal plants and nanotechnology is an emerging marvel in medicine that has delivered promising results in the treatment of AD and PD. The present review aims to reveal the therapeutic potential of emerging nanoformulations of Phytocompounds for the treatment and management of AD and PD.